Allgens(SH:688613) Sou Hu Cai Jing·2025-09-11 00:28Core Viewpoint - The stock of Aojing Medical (688613) has experienced a decline of 4.4% as of September 10, 2025, closing at 25.42 yuan, with significant net outflows from major funds and a mixed performance from retail investors [1][2]. Financial Performance - Aojing Medical reported a main revenue of 100 million yuan for the first half of 2025, a year-on-year decrease of 0.2% [5]. - The net profit attributable to shareholders was 7.9753 million yuan, down 13.52% year-on-year [5]. - The second quarter of 2025 showed a single-quarter main revenue of 57.5772 million yuan, an increase of 8.88% year-on-year, and a net profit of 6.9338 million yuan, up 203.59% year-on-year [5]. Market Activity - On September 10, 2025, the stock had a trading volume of 134,700 hands and a transaction amount of 341 million yuan [1]. - The net outflow of major funds was 45.0152 million yuan, accounting for 13.21% of the total transaction amount, while retail investors saw a net inflow of 33.3271 million yuan, representing 9.78% of the total [1][2]. Financing and Margin Trading - As of September 10, 2025, the financing balance was 178 million yuan, with a net financing purchase of 2.518 million yuan [3]. - There were no short selling activities reported on that day, indicating a stable margin trading environment [3]. Industry Comparison - Aojing Medical's total market capitalization is 3.483 billion yuan, significantly lower than the industry average of 12.107 billion yuan, ranking 97 out of 123 in the medical device sector [5]. - The company's gross margin stands at 63.12%, which is above the industry average of 51.85%, ranking 42 out of 123 [5].